Herbs (Global Traditional) · Amazonian
Catuaba (Erythroxylum catuaba) (Erythroxylum catuaba)
Moderate Evidencebotanical1 PubMed Study
Hermetica Superfood Encyclopedia
Catuaba (Erythroxylum catuaba) is an Amazonian bark containing alkaloids like catubine that modulate dopamine and serotonin neurotransmitter systems. Research demonstrates neuroprotective effects against oxidative stress and preliminary antidepressant-like activity in animal models.
Catuaba refers to the bark of Trichilia catigua A. Juss. (Meliaceae family), a small tree native to the Brazilian Amazon rainforest. The active material is extracted from its stem bark using hydroalcoholic extraction methods, yielding crude extracts rich in bioactive polyphenols and related phytochemicals.
No human clinical trials, randomized controlled trials (RCTs), or meta-analyses have been conducted on Catuaba. All evidence is limited to preclinical animal and in vitro studies, including rodent forced swimming tests showing dopaminergic antidepressant effects (PMID: 15991001), rat hippocampal neuroprotection studies (PMID: 23001398), and reproductive safety assessments showing potential embryotoxicity at 400 mg/kg (PMID: 25792016).
No clinically studied human dosages exist. Preclinical rodent studies used hydroalcoholic extracts at 25-250 mg/kg orally for antifatigue effects over 7 weeks, and 400 mg/kg showed embryotoxic effects in pregnant rats. No standardized human dosage ranges or extract specifications are available. Consult a healthcare provider before starting any new supplement.
Catuaba bark (Erythroxylum catuaba) is not consumed as a macronutrient source; typical preparations are bark decoctions or standardized extracts with negligible caloric, protein, fat, or carbohydrate contribution at functional doses. Key bioactive compounds include: (1) Catuabines A, B, and C — tropane alkaloids structurally related to cocaine-family alkaloids but lacking significant stimulant activity, present at approximately 0.05–0.3% dry weight of bark; these are considered primary neuroactive constituents responsible for dopaminergic and serotonergic modulation. (2) Cinchonains (condensed tannin-flavan-3-ol oligomers, including cinchonain Ia and Ib) at approximately 1–3% dry bark weight, contributing antioxidant capacity (ORAC values estimated in the range of 3,000–8,000 μmol TE/g for concentrated extracts). (3) Flavonoids including epicatechin and catechin derivatives, approximately 0.5–1.5% dry weight. (4) Terpenes including cyclolignans and a small fraction of essential oils (~0.1–0.4%). (5) Saponins at low concentrations (<0.5% dry weight). Mineral content is modest and preparation-dependent: bark decoctions may yield trace potassium (~50–150 mg/L), calcium (~10–40 mg/L), and magnesium (~5–20 mg/L) per typical serving volume (200–250 mL). No meaningful vitamin content has been documented in pharmacognostic analyses. Bioavailability: alkaloid absorption is presumed to occur via gastrointestinal mucosa following oral ingestion; cinchonains have limited oral bioavailability due to molecular size and tannin binding to gut proteins, though they may exert local antioxidant effects; lipophilic alkaloid fractions show better absorption. Standardized extracts are typically characterized by total alkaloid content (0.02–0.1% in commercial preparations) rather than specific catuabine concentrations, limiting precise dosing comparisons across studies.
Catuaba's alkaloid compounds, particularly catubine, modulate dopaminergic and serotonergic neurotransmitter pathways in the brain. The extract provides neuroprotection by reducing oxidative stress markers and protecting against ischemia-reperfusion injury in hippocampal tissue. These mechanisms contribute to its observed antidepressant-like effects and enhanced physical performance.
Current evidence for catuaba comes primarily from animal studies and ex vivo tissue research. Rat hippocampal studies showed neuroprotective effects at concentrations of 40-100 μg/mL against oxidative damage. Animal behavioral studies demonstrated antidepressant-like effects through neurotransmitter modulation. Human clinical trials are lacking, limiting the strength of evidence for therapeutic applications.
Catuaba is generally well-tolerated with minimal reported side effects in traditional use. Potential interactions may occur with psychiatric medications due to its effects on dopamine and serotonin systems. Safety during pregnancy and breastfeeding has not been established. Individuals taking antidepressants or other mood-affecting medications should consult healthcare providers before use.
